News Sentiment

ALLO sentiment intelligence

Allogene Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.00 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-3.8% over one week, +5.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Allogene’s ALLO-316 Achieves 31% Response Rate in Advanced Renal Cell Carcinoma

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -3.8% Price reacting lower
Trend fit Trend inactive 5.3% over four weeks
Fair value -16.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 43
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 11
TradingView 7
simplywall.st 4
GlobeNewswire 3
Quartr 2
The Business Journals 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 17
Regulatory and legal 3
Analyst action 3
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
Insider Monkey Direct company coverage

10 Small Cap Stocks with Potential to Rise 1000 Percent

This article highlights small-cap stocks with significant growth potential, focusing on Allogene Therapeutics, Inc. (NASDAQ:ALLO) as a key example. Allogene is a clinical-stage biotechnology company developing CAR T cell therapies for cancer and autoimmune diseases, with importan

Tone
Positive 75/100
Event
Market update
Published
16 Jun 2026 14:09
Source
Insider Monkey
Barchart.com Direct company coverage

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut

DelveInsight projects the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market to be a high-growth healthcare investment space through 2036, driven by rising NHL prevalence and advancements in CAR T-cell therapies. The report highlights key companies like Gilead Sciences, Novarti

Tone
Positive 66/100
Event
Market update
Published
12 Jun 2026 01:09
Source
Barchart.com
Insider Monkey Direct company coverage

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio

Allogene Therapeutics (ALLO) is highlighted as a top penny stock due to its robust CAR T-cell therapy pipeline, including positive interim results for cema-cel in the ALPHA3 trial and development of ALLO-329 for autoimmune disease. The company reported a net loss of $42.6 million

Tone
Positive 71/100
Event
Earnings
Published
07 Jun 2026 13:57
Source
Insider Monkey
Stocktwits Direct company coverage

ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’

Allogene Therapeutics (ALLO) shares surged over 50% to a two-year high after interim Phase 2 trial data for Cema-Cel in treating lymphoma showed significant efficacy. The data revealed 58.3% of treated patients had no detectable disease and a 97.7% drop in cancer DNA levels, lead

Tone
Positive 94/100
Event
Analyst action
Published
06 Jun 2026 22:10
Source
Stocktwits
The Business Journals Direct company coverage

A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test

David Chang, co-founder of Allogene Therapeutics Inc., is stepping down as CEO at the end of June. This leadership change occurs as the company is conducting a critical clinical trial for a potential regulatory approval of its lymphoma treatment. The San Francisco Business Times

Tone
Neutral 50/100
Event
Regulatory and legal
Published
01 Jun 2026 20:40
Source
The Business Journals
The Globe and Mail Direct company coverage

Allogene Therapeutics Names Zachary Roberts as New CEO

Allogene Therapeutics has appointed Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding co-founder David Chang. Roberts, currently EVP of R&D and Chief Medical Officer, will also join the board, bringing extensive oncology and cell therapy experience

Tone
Positive 60/100
Event
Market update
Published
30 May 2026 20:39
Source
The Globe and Mail